




# Innovating to end HIV

## An increasingly robust portfolio

Unitaid's investments in HIV and related illnesses have more than doubled in 4 years, and they make up nearly half of our US\$ 1.3 billion grant portfolio.




## Our game-changing investments include



### Prevention

Preventive medicines (PrEP) for people at high risk

**\$ 37 m**



### HIV-related illnesses

Better tools to screen, prevent and treat coinfections and comorbidities in people living with HIV (advanced HIV disease, cervical cancer, hepatitis C)

**\$ 126.5 m**



### Testing

HIV self-testing to increase the number of people living with HIV that are aware of their status and improved infant diagnosis

**\$ 213.3 m**



### Our portfolio keeps growing

including the funding to enabling programs such as the WHO prequalification and the Medicines Patent Pool



### Treatment and monitoring

Antiretroviral treatments that are cheaper, safer and less prone to drug resistance as well as formulations adapted for children. Viral load tests to monitor if the treatments are working

**\$ 99.2 m**